Actively Recruiting
Hemorrhage Stroke Decision Making Model Based Deep Learning (BrainHemoAI System)
Led by Second Affiliated Hospital of Nanchang University · Updated on 2026-05-06
7100
Participants Needed
1
Research Sites
225 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital of Nanchang University
Lead Sponsor
F
First Affiliated Hospital of Gannan Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Although hemorrhagic stroke also has the characteristics of high mortality and disability rates, and constitutes a major public health problem worldwide, there is a relative lack of in-depth research teams for hemorrhagic stroke in China. The current preoperative imaging evaluation of spontaneous cerebral hemorrhage is still limited to the traditional Tada formula, and there are subjective differences in diagnosis among different doctors, making it difficult to achieve homogenization in clinical decision-making. Hemorrhagic stroke is a common and frequently occurring disease in Jiangxi Province. Therefore, establishing a new diagnosis and treatment system focused on hemorrhagic stroke can not only fill the research gap in this field in China, improve the accuracy and homogeneity of hemorrhagic stroke diagnosis and treatment, but also promote related research progress to reduce the mortality and disability rates of this disease and improve the clinical prognosis of patients.
CONDITIONS
Official Title
Hemorrhage Stroke Decision Making Model Based Deep Learning (BrainHemoAI System)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 8 years or older
- Diagnosed with spontaneous hemorrhagic stroke based on medical history and tests
- Received non-contrast computed tomography (NCCT) in outpatient or emergency
- Treated following standard clinical guidelines during hospitalization
- Have complete clinical data available
You will not qualify if you...
- Had surgery at another hospital before admission
- In shock upon admission
- Severe heart, liver, or kidney failure or other life-threatening diseases
- Died during hospitalization
- Expected lifespan less than six months or unable to complete study follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Nanchang University
Nanchang, China
Actively Recruiting
Research Team
X
Xingen Zhu, Prof
CONTACT
P
Ping Hu, PhD;MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here